{"transactions":[{"id":719873,"issuer":{"id":4691,"kind":"organization","name":"CONMED Corp","symbol":"CNMD"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"director":true}}],"security":"RSUs (Restricted Stock Units)","published_at":"2026-07-02T21:12:40.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":5603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the \"Company\") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period."}],"balance_after":5603,"derivative":{"exercise_price":0,"exercise_date":"2027-07-01","expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":5603},"source":{"system":"sec-edgar","filing":"0000816956-26-000085","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816956/000081695626000085/form4.xml","form_type":"4"}},{"id":1247749,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-25T21:41:43.000Z","date":"2025-02-25","kind":"sale","planned":true,"acquired":false,"shares":2688,"price":104,"value":279552.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024."}],"balance_after":25766,"source":{"system":"sec-edgar","filing":"0001225208-25-002386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825002386/doc4.xml","form_type":"4"}},{"id":1247748,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-25T21:41:43.000Z","date":"2025-02-24","kind":"sale","planned":true,"acquired":false,"shares":4675,"price":104.25,"value":487368.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024."}],"balance_after":28454,"source":{"system":"sec-edgar","filing":"0001225208-25-002386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825002386/doc4.xml","form_type":"4"}},{"id":1262012,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-19T21:23:46.000Z","date":"2025-02-19","kind":"sale","planned":true,"acquired":false,"shares":1510,"price":105.35,"value":159078.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024."}],"balance_after":33129,"source":{"system":"sec-edgar","filing":"0001225208-25-001970","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001970/doc4.xml","form_type":"4"}},{"id":1265187,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-17","kind":"exercise","planned":false,"acquired":false,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2025-02-17","underlying":"Common Stock","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1265186,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":false,"shares":2970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."}],"balance_after":2970,"derivative":{"expiration_date":"2026-02-16","underlying":"Common Stock","underlying_shares":2970},"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1265185,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":false,"shares":2776,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant."}],"balance_after":5552,"derivative":{"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":2776},"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1265184,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":13334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant."}],"balance_after":13334,"derivative":{"exercise_price":106.14,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":13334},"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1265183,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":5181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant."}],"balance_after":5181,"derivative":{"expiration_date":"2029-02-13","underlying":"Common Stock","underlying_shares":5181},"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1265182,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":1521,"price":106.11,"value":161393.31,"ownership":{"direct":true},"balance_after":34639,"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1265181,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-17","kind":"exercise","planned":false,"acquired":true,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":36160,"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1265180,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1355,"price":106.11,"value":143779.05,"ownership":{"direct":true},"balance_after":32826,"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1265179,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":true,"shares":2970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":34181,"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1265178,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1266,"price":106.11,"value":134335.26,"ownership":{"direct":true},"balance_after":31211,"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1265177,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-18T22:52:13.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":true,"shares":2776,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":32477,"source":{"system":"sec-edgar","filing":"0001225208-25-001874","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001874/doc4.xml","form_type":"4"}},{"id":1268466,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2025-02-14T22:29:54.000Z","date":"2025-02-12","kind":"exercise","planned":false,"acquired":false,"shares":2115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant."}],"balance_after":6347,"derivative":{"expiration_date":"2028-02-12","underlying":"Common Stock","underlying_shares":2115},"source":{"system":"sec-edgar","filing":"0001225208-25-001793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001793/doc4.xml","form_type":"4"}},{"id":1268465,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-14T22:29:54.000Z","date":"2025-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":868,"price":105.77,"value":91808.36,"ownership":{"direct":true},"balance_after":29701,"source":{"system":"sec-edgar","filing":"0001225208-25-001793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001793/doc4.xml","form_type":"4"}},{"id":1268464,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-14T22:29:54.000Z","date":"2025-02-12","kind":"exercise","planned":false,"acquired":true,"shares":2115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":30569,"source":{"system":"sec-edgar","filing":"0001225208-25-001793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001793/doc4.xml","form_type":"4"}},{"id":1270355,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-13T21:32:45.000Z","date":"2025-02-12","kind":"sale","planned":true,"acquired":false,"shares":13022,"price":105.0586,"value":1368073.0892,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.787 to $105.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":28454,"source":{"system":"sec-edgar","filing":"0001225208-25-001685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001685/doc4.xml","form_type":"4"}},{"id":1270354,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-13T21:32:45.000Z","date":"2025-02-11","kind":"tax_withholding","planned":true,"acquired":false,"shares":10738,"price":105.98,"value":1138013.24,"ownership":{"direct":true},"balance_after":41476,"source":{"system":"sec-edgar","filing":"0001225208-25-001685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001685/doc4.xml","form_type":"4"}},{"id":1270353,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-02-13T21:32:45.000Z","date":"2025-02-11","kind":"grant","planned":true,"acquired":true,"shares":23760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied."}],"balance_after":52214,"source":{"system":"sec-edgar","filing":"0001225208-25-001685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825001685/doc4.xml","form_type":"4"}},{"id":1317033,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Performance Share Units","published_at":"2025-01-03T21:32:57.000Z","date":"2025-01-01","kind":"exercise","planned":true,"acquired":false,"shares":10430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024."}],"balance_after":0,"derivative":{"exercise_date":"2024-12-31","expiration_date":"2024-12-31","underlying":"Common Stock","underlying_shares":10430},"source":{"system":"sec-edgar","filing":"0001225208-25-000206","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825000206/doc4.xml","form_type":"4"}},{"id":1317032,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-01-03T21:32:57.000Z","date":"2025-01-03","kind":"sale","planned":true,"acquired":false,"shares":7152,"price":89.8571,"value":642657.9792,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.523 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":28454,"source":{"system":"sec-edgar","filing":"0001225208-25-000206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825000206/doc4.xml","form_type":"4"}},{"id":1317031,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-01-03T21:32:57.000Z","date":"2025-01-01","kind":"tax_withholding","planned":true,"acquired":false,"shares":3278,"price":89.32,"value":292790.96,"ownership":{"direct":true},"balance_after":35606,"source":{"system":"sec-edgar","filing":"0001225208-25-000206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825000206/doc4.xml","form_type":"4"}},{"id":1317030,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2025-01-03T21:32:57.000Z","date":"2025-01-01","kind":"exercise","planned":true,"acquired":true,"shares":10430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired on June 30, 2024 under the Company's Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":38884,"source":{"system":"sec-edgar","filing":"0001225208-25-000206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520825000206/doc4.xml","form_type":"4"}},{"id":1498471,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-30T20:27:23.000Z","date":"2024-05-29","kind":"exercise","planned":true,"acquired":false,"shares":33726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":17.26,"expiration_date":"2026-02-22","underlying":"Common Stock","underlying_shares":33726},"source":{"system":"sec-edgar","filing":"0001225208-24-006445","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824006445/doc4.xml","form_type":"4"}},{"id":1498470,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-05-30T20:27:23.000Z","date":"2024-05-29","kind":"sale","planned":true,"acquired":false,"shares":63802,"price":75.0987,"value":4791447.2574,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $74.78 to $75.33, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":28022,"source":{"system":"sec-edgar","filing":"0001225208-24-006445","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824006445/doc4.xml","form_type":"4"}},{"id":1498469,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-05-30T20:27:23.000Z","date":"2024-05-29","kind":"exercise","planned":true,"acquired":true,"shares":33726,"price":17.26,"value":582110.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024."}],"balance_after":91824,"source":{"system":"sec-edgar","filing":"0001225208-24-006445","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824006445/doc4.xml","form_type":"4"}},{"id":1570772,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-03-19T20:41:02.000Z","date":"2024-03-18","kind":"sale","planned":true,"acquired":false,"shares":14506,"price":66.4504,"value":963929.5024,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $66.26 to $66.791, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":58098,"source":{"system":"sec-edgar","filing":"0001225208-24-004316","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824004316/doc4.xml","form_type":"4"}},{"id":1626682,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-22T21:19:47.000Z","date":"2024-02-21","kind":"sale","planned":true,"acquired":false,"shares":4960,"price":66.35,"value":329096.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."}],"balance_after":72604,"source":{"system":"sec-edgar","filing":"0001225208-24-002707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002707/doc4.xml","form_type":"4"}},{"id":1635702,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Deferred Stock Units","published_at":"2024-02-21T02:04:53.000Z","date":"2024-02-18","kind":"exercise","planned":false,"acquired":false,"shares":2817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":2817},"source":{"system":"sec-edgar","filing":"0001225208-24-002577","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002577/doc4.xml","form_type":"4"}},{"id":1635701,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2024-02-21T02:04:53.000Z","date":"2024-02-17","kind":"exercise","planned":false,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."}],"balance_after":3334,"derivative":{"expiration_date":"2025-02-17","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001225208-24-002577","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002577/doc4.xml","form_type":"4"}},{"id":1635700,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2024-02-21T02:04:53.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":false,"shares":2970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."}],"balance_after":5940,"derivative":{"expiration_date":"2026-02-16","underlying":"Common Stock","underlying_shares":2970},"source":{"system":"sec-edgar","filing":"0001225208-24-002577","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002577/doc4.xml","form_type":"4"}},{"id":1635699,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-21T02:04:53.000Z","date":"2024-02-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":1285,"price":65.82,"value":84578.7,"ownership":{"direct":true},"balance_after":77564,"source":{"system":"sec-edgar","filing":"0001225208-24-002577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002577/doc4.xml","form_type":"4"}},{"id":1635698,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-21T02:04:53.000Z","date":"2024-02-18","kind":"exercise","planned":false,"acquired":true,"shares":2817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock."}],"balance_after":78849,"source":{"system":"sec-edgar","filing":"0001225208-24-002577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002577/doc4.xml","form_type":"4"}},{"id":1635697,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-21T02:04:53.000Z","date":"2024-02-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":1520,"price":65.82,"value":100046.4,"ownership":{"direct":true},"balance_after":76032,"source":{"system":"sec-edgar","filing":"0001225208-24-002577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002577/doc4.xml","form_type":"4"}},{"id":1635696,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-21T02:04:53.000Z","date":"2024-02-17","kind":"exercise","planned":false,"acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":77552,"source":{"system":"sec-edgar","filing":"0001225208-24-002577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002577/doc4.xml","form_type":"4"}},{"id":1635695,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-21T02:04:53.000Z","date":"2024-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1355,"price":65.82,"value":89186.1,"ownership":{"direct":true},"balance_after":74219,"source":{"system":"sec-edgar","filing":"0001225208-24-002577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002577/doc4.xml","form_type":"4"}},{"id":1635694,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-21T02:04:53.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":true,"shares":2970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":75574,"source":{"system":"sec-edgar","filing":"0001225208-24-002577","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002577/doc4.xml","form_type":"4"}},{"id":1639490,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2024-02-16T21:22:07.000Z","date":"2024-02-14","kind":"exercise","planned":false,"acquired":false,"shares":2776,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant."}],"balance_after":8328,"derivative":{"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":2776},"source":{"system":"sec-edgar","filing":"0001225208-24-002306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002306/doc4.xml","form_type":"4"}},{"id":1639489,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-16T21:22:07.000Z","date":"2024-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":1266,"price":65.95,"value":83492.7,"ownership":{"direct":true},"balance_after":72604,"source":{"system":"sec-edgar","filing":"0001225208-24-002306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002306/doc4.xml","form_type":"4"}},{"id":1639488,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-16T21:22:07.000Z","date":"2024-02-14","kind":"exercise","planned":false,"acquired":true,"shares":2776,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":73870,"source":{"system":"sec-edgar","filing":"0001225208-24-002306","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002306/doc4.xml","form_type":"4"}},{"id":1644216,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T21:22:51.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":22311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant."}],"balance_after":22311,"derivative":{"exercise_price":64.99,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":22311},"source":{"system":"sec-edgar","filing":"0001225208-24-002046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002046/doc4.xml","form_type":"4"}},{"id":1644215,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2024-02-14T21:22:51.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":8462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant."}],"balance_after":8462,"derivative":{"expiration_date":"2028-02-12","underlying":"Common Stock","underlying_shares":8462},"source":{"system":"sec-edgar","filing":"0001225208-24-002046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824002046/doc4.xml","form_type":"4"}},{"id":1654306,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-08T21:36:19.000Z","date":"2024-02-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":12160,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":71094,"source":{"system":"sec-edgar","filing":"0001225208-24-001781","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824001781/doc4.xml","form_type":"4"}},{"id":1654305,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-02-08T21:36:19.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":26666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2023 and subject to the completion of the concurrent three-year individual service period. On February 6, 2024, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied."}],"balance_after":83254,"source":{"system":"sec-edgar","filing":"0001225208-24-001781","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824001781/doc4.xml","form_type":"4"}},{"id":1681963,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-10T22:44:53.000Z","date":"2024-01-09","kind":"exercise","planned":true,"acquired":false,"shares":15172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":16.31,"expiration_date":"2025-02-23","underlying":"Common Stock","underlying_shares":15172},"source":{"system":"sec-edgar","filing":"0001225208-24-000738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824000738/doc4.xml","form_type":"4"}},{"id":1681962,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-01-10T22:44:53.000Z","date":"2024-01-09","kind":"sale","planned":true,"acquired":false,"shares":15172,"price":59.25,"value":898941.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."}],"balance_after":56588,"source":{"system":"sec-edgar","filing":"0001225208-24-000738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824000738/doc4.xml","form_type":"4"}},{"id":1681961,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-01-10T22:44:53.000Z","date":"2024-01-09","kind":"exercise","planned":true,"acquired":true,"shares":15172,"price":16.31,"value":247455.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."}],"balance_after":71760,"source":{"system":"sec-edgar","filing":"0001225208-24-000738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824000738/doc4.xml","form_type":"4"}},{"id":1686368,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-05T21:53:53.000Z","date":"2024-01-04","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant."}],"balance_after":15172,"derivative":{"exercise_price":16.31,"expiration_date":"2025-02-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001225208-24-000467","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824000467/doc4.xml","form_type":"4"}},{"id":1686367,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-01-05T21:53:53.000Z","date":"2024-01-04","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":58.4001,"value":876001.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $58.40 to $58.405, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":56588,"source":{"system":"sec-edgar","filing":"0001225208-24-000467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824000467/doc4.xml","form_type":"4"}},{"id":1686366,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-01-05T21:53:53.000Z","date":"2024-01-04","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":16.31,"value":244650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."}],"balance_after":71588,"source":{"system":"sec-edgar","filing":"0001225208-24-000467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824000467/doc4.xml","form_type":"4"}},{"id":1689344,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-01-04T21:15:10.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":11931,"price":57.821,"value":689862.351,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $57.65 to $58.02, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":56588,"source":{"system":"sec-edgar","filing":"0001225208-24-000380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824000380/doc4.xml","form_type":"4"}},{"id":1697177,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Performance Share Units","published_at":"2024-01-03T01:31:30.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":false,"shares":17439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023."}],"balance_after":0,"derivative":{"exercise_date":"2023-12-31","expiration_date":"2023-12-31","underlying":"Common Stock","underlying_shares":17439},"source":{"system":"sec-edgar","filing":"0001225208-24-000109","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824000109/doc4.xml","form_type":"4"}},{"id":1697176,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-01-03T01:31:30.000Z","date":"2024-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":5508,"price":57.81,"value":318417.48,"ownership":{"direct":true},"balance_after":68519,"source":{"system":"sec-edgar","filing":"0001225208-24-000109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824000109/doc4.xml","form_type":"4"}},{"id":1697175,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2024-01-03T01:31:30.000Z","date":"2024-01-01","kind":"exercise","planned":false,"acquired":true,"shares":17439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023."}],"balance_after":74027,"source":{"system":"sec-edgar","filing":"0001225208-24-000109","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520824000109/doc4.xml","form_type":"4"}},{"id":1719442,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-12-07T21:10:43.000Z","date":"2023-12-06","kind":"sale","planned":true,"acquired":false,"shares":353,"price":55.03,"value":19425.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."}],"balance_after":56588,"source":{"system":"sec-edgar","filing":"0001225208-23-010827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823010827/doc4.xml","form_type":"4"}},{"id":1724526,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Deferred Stock Units","published_at":"2023-12-04T22:42:52.000Z","date":"2023-12-03","kind":"exercise","planned":false,"acquired":false,"shares":649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2023-12-03","underlying":"Common Stock","underlying_shares":649},"source":{"system":"sec-edgar","filing":"0001225208-23-010679","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823010679/doc4.xml","form_type":"4"}},{"id":1724525,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-12-04T22:42:52.000Z","date":"2023-12-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":296,"price":56.14,"value":16617.44,"ownership":{"direct":true},"balance_after":56941,"source":{"system":"sec-edgar","filing":"0001225208-23-010679","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823010679/doc4.xml","form_type":"4"}},{"id":1724524,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-12-04T22:42:52.000Z","date":"2023-12-03","kind":"exercise","planned":false,"acquired":true,"shares":649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":57237,"source":{"system":"sec-edgar","filing":"0001225208-23-010679","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823010679/doc4.xml","form_type":"4"}},{"id":1746132,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-11-09T21:14:51.000Z","date":"2023-11-08","kind":"gift","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":56588,"source":{"system":"sec-edgar","filing":"0001225208-23-010129","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823010129/doc4.xml","form_type":"4"}},{"id":1793625,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-08-30T20:10:51.000Z","date":"2023-08-29","kind":"sale","planned":true,"acquired":false,"shares":4657,"price":54.5009,"value":253810.6913,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $54.50 to $54.51, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":60588,"source":{"system":"sec-edgar","filing":"0001225208-23-008555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823008555/doc4.xml","form_type":"4"}},{"id":1793624,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-08-30T20:10:51.000Z","date":"2023-08-28","kind":"sale","planned":true,"acquired":false,"shares":13971,"price":53.14,"value":742418.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired on June 30, 2023 under the Boston Scientific Employee Stock Purchase Plan based upon the most current data available."}],"balance_after":65245,"source":{"system":"sec-edgar","filing":"0001225208-23-008555","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823008555/doc4.xml","form_type":"4"}},{"id":1924160,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-04-06T20:26:10.000Z","date":"2023-04-05","kind":"sale","planned":false,"acquired":false,"shares":4903,"price":50.4,"value":247111.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 23, 2023, intended to comply with the prior version of Rule 10b5-1(c)."}],"balance_after":78673,"source":{"system":"sec-edgar","filing":"0001225208-23-004745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823004745/doc4.xml","form_type":"4"}},{"id":1934450,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-03-31T20:29:01.000Z","date":"2023-03-30","kind":"sale","planned":false,"acquired":false,"shares":4903,"price":49.6,"value":243188.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 23, 2023."}],"balance_after":83576,"source":{"system":"sec-edgar","filing":"0001225208-23-004332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823004332/doc4.xml","form_type":"4"}},{"id":2001489,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Deferred Stock Units","published_at":"2023-02-22T21:55:44.000Z","date":"2023-02-21","kind":"exercise","acquired":false,"shares":2804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":2804},"source":{"system":"sec-edgar","filing":"0001225208-23-002532","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002532/doc4.xml","form_type":"4"}},{"id":2001488,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-22T21:55:44.000Z","date":"2023-02-22","kind":"sale","acquired":false,"shares":3340,"price":46.1,"value":153974.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."}],"balance_after":88479,"source":{"system":"sec-edgar","filing":"0001225208-23-002532","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002532/doc4.xml","form_type":"4"}},{"id":2001487,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-22T21:55:44.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":2313,"price":46.32,"value":107138.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."}],"balance_after":91819,"source":{"system":"sec-edgar","filing":"0001225208-23-002532","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002532/doc4.xml","form_type":"4"}},{"id":2001486,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-22T21:55:44.000Z","date":"2023-02-21","kind":"tax_withholding","acquired":false,"shares":1279,"price":46.23,"value":59128.17,"ownership":{"direct":true},"balance_after":94132,"source":{"system":"sec-edgar","filing":"0001225208-23-002532","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002532/doc4.xml","form_type":"4"}},{"id":2001485,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-22T21:55:44.000Z","date":"2023-02-21","kind":"exercise","acquired":true,"shares":2804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":95411,"source":{"system":"sec-edgar","filing":"0001225208-23-002532","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002532/doc4.xml","form_type":"4"}},{"id":2004928,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Deferred Stock Units","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-18","kind":"exercise","acquired":false,"shares":2817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant."}],"balance_after":2817,"derivative":{"expiration_date":"2024-02-18","underlying":"Common Stock","underlying_shares":2817},"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2004927,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-17","kind":"exercise","acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant."}],"balance_after":6667,"derivative":{"expiration_date":"2025-02-17","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2004926,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-16","kind":"exercise","acquired":false,"shares":2970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant."}],"balance_after":8910,"derivative":{"expiration_date":"2026-02-16","underlying":"Common Stock","underlying_shares":2970},"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2004925,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-18","kind":"tax_withholding","acquired":false,"shares":1002,"price":46.54,"value":46633.08,"ownership":{"direct":true},"balance_after":92607,"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2004924,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-18","kind":"exercise","acquired":true,"shares":2817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock."}],"balance_after":93609,"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2004923,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-17","kind":"sale","acquired":false,"shares":2061,"price":46.35,"value":95527.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."}],"balance_after":90792,"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2004922,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-17","kind":"tax_withholding","acquired":false,"shares":1020,"price":46.54,"value":47470.8,"ownership":{"direct":true},"balance_after":92853,"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2004921,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-17","kind":"exercise","acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":93873,"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2004920,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-16","kind":"sale","acquired":false,"shares":1409,"price":46.79,"value":65927.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."}],"balance_after":90540,"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2004919,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-16","kind":"tax_withholding","acquired":false,"shares":909,"price":46.48,"value":42250.32,"ownership":{"direct":true},"balance_after":91949,"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2004918,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-21T21:19:32.000Z","date":"2023-02-16","kind":"exercise","acquired":true,"shares":2970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":92858,"source":{"system":"sec-edgar","filing":"0001225208-23-002378","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002378/doc4.xml","form_type":"4"}},{"id":2012143,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Deferred Stock Units","published_at":"2023-02-17T00:17:18.000Z","date":"2023-02-15","kind":"exercise","acquired":false,"shares":2031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"expiration_date":"2023-02-15","underlying":"Common Stock","underlying_shares":2031},"source":{"system":"sec-edgar","filing":"0001225208-23-002154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002154/doc4.xml","form_type":"4"}},{"id":2012142,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-17T00:17:18.000Z","date":"2023-02-15","kind":"tax_withholding","acquired":false,"shares":622,"price":47.29,"value":29414.38,"ownership":{"direct":true},"balance_after":89888,"source":{"system":"sec-edgar","filing":"0001225208-23-002154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002154/doc4.xml","form_type":"4"}},{"id":2012141,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-02-17T00:17:18.000Z","date":"2023-02-15","kind":"exercise","acquired":true,"shares":2031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":90510,"source":{"system":"sec-edgar","filing":"0001225208-23-002154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002154/doc4.xml","form_type":"4"}},{"id":2014318,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T22:44:02.000Z","date":"2023-02-14","kind":"grant","acquired":true,"shares":28893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant."}],"balance_after":28893,"derivative":{"exercise_price":47.28,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":28893},"source":{"system":"sec-edgar","filing":"0001225208-23-002038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002038/doc4.xml","form_type":"4"}},{"id":2014317,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Restricted Stock Units","published_at":"2023-02-15T22:44:02.000Z","date":"2023-02-14","kind":"grant","acquired":true,"shares":11104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant."}],"balance_after":11104,"derivative":{"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":11104},"source":{"system":"sec-edgar","filing":"0001225208-23-002038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002038/doc4.xml","form_type":"4"}},{"id":2014316,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Performance Share Units","published_at":"2023-02-15T22:44:02.000Z","date":"2023-02-14","kind":"grant","acquired":true,"shares":10430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024."}],"balance_after":10430,"derivative":{"exercise_date":"2024-12-31","expiration_date":"2024-12-31","underlying":"Common Stock","underlying_shares":10430},"source":{"system":"sec-edgar","filing":"0001225208-23-002038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823002038/doc4.xml","form_type":"4"}},{"id":2070391,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-01-04T21:21:27.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":6751,"price":46.3817,"value":313122.8567,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $46.18 to $46.54, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":88479,"source":{"system":"sec-edgar","filing":"0001225208-23-000178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823000178/doc4.xml","form_type":"4"}},{"id":2073471,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Performance Share Units","published_at":"2023-01-03T21:26:39.000Z","date":"2023-01-01","kind":"exercise","acquired":false,"shares":9981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022."}],"balance_after":0,"derivative":{"exercise_date":"2022-12-31","expiration_date":"2022-12-31","underlying":"Common Stock","underlying_shares":9981},"source":{"system":"sec-edgar","filing":"0001225208-23-000052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823000052/doc4.xml","form_type":"4"}},{"id":2073470,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-01-03T21:26:39.000Z","date":"2023-01-01","kind":"tax_withholding","acquired":false,"shares":3230,"price":46.27,"value":149452.1,"ownership":{"direct":true},"balance_after":95230,"source":{"system":"sec-edgar","filing":"0001225208-23-000052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823000052/doc4.xml","form_type":"4"}},{"id":2073469,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2023-01-03T21:26:39.000Z","date":"2023-01-01","kind":"exercise","acquired":true,"shares":9981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2022."}],"balance_after":98460,"source":{"system":"sec-edgar","filing":"0001225208-23-000052","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520823000052/doc4.xml","form_type":"4"}},{"id":2088736,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2022-12-13T21:49:16.000Z","date":"2022-12-12","kind":"sale","acquired":false,"shares":11080,"price":46.75,"value":517990.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan."}],"balance_after":88479,"source":{"system":"sec-edgar","filing":"0001225208-22-012606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822012606/doc4.xml","form_type":"4"}},{"id":2090392,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-12T21:26:49.000Z","date":"2022-12-09","kind":"exercise","acquired":false,"shares":29599,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":13.08,"expiration_date":"2024-02-24","underlying":"Common Stock","underlying_shares":29599},"source":{"system":"sec-edgar","filing":"0001225208-22-012558","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822012558/doc4.xml","form_type":"4"}},{"id":2090391,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2022-12-12T21:26:49.000Z","date":"2022-12-09","kind":"sale","acquired":false,"shares":41032,"price":46.147,"value":1893503.704,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $45.97 to $46.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":99559,"source":{"system":"sec-edgar","filing":"0001225208-22-012558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822012558/doc4.xml","form_type":"4"}},{"id":2090390,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2022-12-12T21:26:49.000Z","date":"2022-12-09","kind":"exercise","acquired":true,"shares":29599,"price":13.08,"value":387154.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan."}],"balance_after":140591,"source":{"system":"sec-edgar","filing":"0001225208-22-012558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822012558/doc4.xml","form_type":"4"}},{"id":2097150,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Deferred Stock Units","published_at":"2022-12-05T21:20:41.000Z","date":"2022-12-03","kind":"exercise","acquired":false,"shares":649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant."}],"balance_after":649,"derivative":{"expiration_date":"2023-12-03","underlying":"Common Stock","underlying_shares":649},"source":{"system":"sec-edgar","filing":"0001225208-22-012296","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822012296/doc4.xml","form_type":"4"}},{"id":2097149,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2022-12-05T21:20:41.000Z","date":"2022-12-03","kind":"tax_withholding","acquired":false,"shares":296,"price":46.6,"value":13793.6,"ownership":{"direct":true},"balance_after":110992,"source":{"system":"sec-edgar","filing":"0001225208-22-012296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822012296/doc4.xml","form_type":"4"}},{"id":2097148,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2022-12-05T21:20:41.000Z","date":"2022-12-03","kind":"exercise","acquired":true,"shares":649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock."}],"balance_after":111288,"source":{"system":"sec-edgar","filing":"0001225208-22-012296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822012296/doc4.xml","form_type":"4"}},{"id":2097147,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2022-12-05T21:20:41.000Z","date":"2022-11-01","kind":"gift","acquired":false,"shares":230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes shares acquired on June 30, 2022 under the Boston Scientific Employee Stock Purchase Plan (formerly Boston Scientific Global Employee Stock Purchase Plan) based upon the most current data available."}],"balance_after":110639,"source":{"system":"sec-edgar","filing":"0001225208-22-012296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822012296/doc4.xml","form_type":"4"}},{"id":2097146,"issuer":{"id":1897,"kind":"organization","name":"BOSTON SCIENTIFIC CORP","symbol":"BSX"},"owners":[{"id":33438,"kind":"person","name":"Mirviss Jeffrey B.","position":1,"cik":"0001566094","reported_name":"Mirviss Jeffrey B.","relationship":{"officer":true,"officer_title":"EVP&Pres, Periph Intervent"}}],"security":"Common Stock","published_at":"2022-12-05T21:20:41.000Z","date":"2022-05-16","kind":"gift","acquired":false,"shares":26,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":110290,"source":{"system":"sec-edgar","filing":"0001225208-22-012296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/885725/000122520822012296/doc4.xml","form_type":"4"}}],"next_cursor":"2022-12-05T21:20:41.000000Z,2097146"}